DK1353948T3 - Soluble biological analogs for beta-amyloid peptide - Google Patents

Soluble biological analogs for beta-amyloid peptide

Info

Publication number
DK1353948T3
DK1353948T3 DK01990584T DK01990584T DK1353948T3 DK 1353948 T3 DK1353948 T3 DK 1353948T3 DK 01990584 T DK01990584 T DK 01990584T DK 01990584 T DK01990584 T DK 01990584T DK 1353948 T3 DK1353948 T3 DK 1353948T3
Authority
DK
Denmark
Prior art keywords
beta
amyloid peptide
soluble biological
biological analogs
analogs
Prior art date
Application number
DK01990584T
Other languages
Danish (da)
Inventor
Herwig Brunner
Afroditi Kapurniotu
Juergen Bernhagen
Original Assignee
Fraunhofer Ges Forschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Ges Forschung filed Critical Fraunhofer Ges Forschung
Application granted granted Critical
Publication of DK1353948T3 publication Critical patent/DK1353948T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention concerns a peptide having the biological activity of an inhibitor of amyloid formation and its diagnostic and medical use.
DK01990584T 2001-01-13 2001-12-21 Soluble biological analogs for beta-amyloid peptide DK1353948T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10101430A DE10101430B4 (en) 2001-01-13 2001-01-13 Soluble cyclic analogues for the modulation of amyloidogenesis

Publications (1)

Publication Number Publication Date
DK1353948T3 true DK1353948T3 (en) 2006-02-27

Family

ID=7670511

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01990584T DK1353948T3 (en) 2001-01-13 2001-12-21 Soluble biological analogs for beta-amyloid peptide

Country Status (10)

Country Link
US (2) US7342091B2 (en)
EP (1) EP1353948B1 (en)
JP (1) JP4079775B2 (en)
AT (1) ATE307143T1 (en)
AU (1) AU2002229677A1 (en)
CA (1) CA2433687A1 (en)
DE (2) DE10101430B4 (en)
DK (1) DK1353948T3 (en)
ES (1) ES2250509T3 (en)
WO (1) WO2002055552A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
EP1676859A1 (en) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
BRPI0619249A2 (en) 2005-11-30 2011-09-20 Abbott Lab anti-globulin-ß antibodies, antigen-binding fractions thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of making said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
CN101506236B (en) 2005-11-30 2012-12-12 雅培制药有限公司 Monoclonal antibodies against amyloid beta protein and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
WO2010002251A1 (en) * 2008-07-01 2010-01-07 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccine against amyloid folding intermediate
MX2011000975A (en) * 2008-07-25 2011-05-25 Abbott Lab Amyloid 㟠peptide analogues, oligomers thereof, processes for preparing and compositions comprising said analogues or oligomers, and their uses.
MX360403B (en) 2010-04-15 2018-10-31 Abbvie Inc Amyloid-beta binding proteins.
JP6147665B2 (en) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド Amyloid beta-binding protein
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
WO2017079835A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
AU2022282576A1 (en) 2021-05-26 2023-12-14 Regain Therapeutics Sweden Ab Compositions and methods for treatment and/or prophylaxis of proteinopathies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
CA2214247C (en) * 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
DE19725619A1 (en) 1997-06-17 1998-12-24 Fraunhofer Ges Forschung Peptides as agonists and / or inhibitors of amyloid formation and cytotoxicity as well as for use in Alzheimer's disease, in type II diabetes mellitus and in spongiform encephalopathies
JP4615727B2 (en) * 1998-12-24 2011-01-19 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Succinoylaminobenzodiazepine as an inhibitor of Aβ protein production
WO2001034631A2 (en) * 1999-11-05 2001-05-17 Axonyx, Inc. PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF

Also Published As

Publication number Publication date
CA2433687A1 (en) 2002-07-18
JP4079775B2 (en) 2008-04-23
EP1353948A2 (en) 2003-10-22
DE10101430A1 (en) 2002-08-01
US20080146508A1 (en) 2008-06-19
DE10101430B4 (en) 2008-10-02
EP1353948B1 (en) 2005-10-19
AU2002229677A1 (en) 2002-07-24
ATE307143T1 (en) 2005-11-15
JP2004526693A (en) 2004-09-02
US20040116337A1 (en) 2004-06-17
ES2250509T3 (en) 2006-04-16
WO2002055552A2 (en) 2002-07-18
US7342091B2 (en) 2008-03-11
WO2002055552A3 (en) 2003-04-24
DE50107777D1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
CO5611160A2 (en) CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOLOGICALLY ACTIVE PEPTIDES
CR8012A (en) ENDOMEDULAR NAIL FOR THE TREATMENT OF PROXIMAL FEMUR FRACTURES
HUP0402029A2 (en) Peptide-based multimeric targeted contrast agents
ATE318590T1 (en) DRUG COMBINATIONS (E.G. CHLORPROMAZINE AND PENTAMIDINE) FOR THE THERAPY OF NEOPLASTIC DISEASES
DK1353948T3 (en) Soluble biological analogs for beta-amyloid peptide
ATE425253T1 (en) TRIBONECTINS
ATE308324T1 (en) ZOLPIDEM HEMITARTRATE
PT1147420E (en) URINARY TRYSPIN INHIBITOR FOR AIDS DIAGNOSIS
MXPA03006776A (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease.
IT1306165B1 (en) USE OF INHIBITORS OF THE SUBSTANCE P FOR THE TREATMENT OF DENOCARCINOMAS.
HUP0302738A2 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
IL158186A0 (en) Pharmaceutically active compounds and methods of use
NO20005548L (en) Mykobakterieinhibitorer
AP2009004857A0 (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures,which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof
DE60215219D1 (en) USE OF DARIFENACINE FOR THE TREATMENT OF THE HARNDRANGS
DE50214523D1 (en) NUCLEOTIDE CARRIER FOR DIAGNOSIS AND THERAPY OF ORAL DISEASES
SE0002417D0 (en) Promote sequences
ATE443695T1 (en) DOUBLE LEASTER
AU2003271954A1 (en) Use of an agent modulating cofilin expresion or activity for the treatment of inflammatory diseases
WO2002097119A3 (en) Use of the indication of the expression of splice variants of gene 21 for the diagnosis and treatment of tumour diseases
UA28113C2 (en) Express test for assaying efficacy of rehabilitation measures
ITRM20030219A1 (en) USE OF LIQUERICE FOR THE PREVENTION AND TREATMENT OF AIDS AND SARS.